Your activity: 9918 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: [email protected]

Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children

Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children
Author:
Joel G Breman, MD, DTPH
Section Editor:
Johanna Daily, MD, MSc
Deputy Editor:
Elinor L Baron, MD, DTMH
Literature review current through: Feb 2022. | This topic last updated: Apr 07, 2020.

INTRODUCTION — The clinical manifestations of malaria vary with parasite species, epidemiology, immunity, and age. In areas where malaria is highly endemic, groups at highest risk include young children (6 to 59 months), who can develop severe illness, and pregnant women, who are at risk for anemia and delivering low birthweight newborns. In areas where malaria is transmitted throughout the year, older children and adults develop partial immunity after repeated infections and are at relatively low risk for severe disease.

Travelers to malarious areas generally have had no previous exposure to malaria parasites or have lost their immunity if they left the endemic area; they are at very high risk for severe disease if infected with Plasmodium falciparum [1,2]. For this reason, it is important to consider malaria in all febrile patients with history of travel to malarious areas.

Issues related to clinical manifestations and diagnosis of malaria will be reviewed here. Technical aspects of laboratory tools for diagnosis of malaria are discussed further separately.

The epidemiology, pathogenesis, diagnosis, and treatment of malaria are discussed separately:

(See "Malaria: Epidemiology, prevention, and control".)

(See "Treatment of uncomplicated falciparum malaria in nonpregnant adults and children".)

(See "Treatment of severe malaria".)

(See "Malaria in pregnancy: Prevention and treatment".)

(See "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae".)

(See "Non-falciparum malaria: Plasmodium knowlesi".)

INCUBATION PERIOD — Following the bite of an infected female Anopheles mosquito, the inoculated sporozoites go to the liver within one to two hours. Individuals are generally asymptomatic for 12 to 35 days but can commence symptoms as early as 7 days (depending on parasite species), until the erythrocytic stage of the parasite life cycle (figure 1). Release of merozoites from infected red cells when they rupture causes fever and the other manifestations of malaria.

In most cases, the incubation period for P. falciparum infection is about 12 to 14 days (range 7 to 30 days); most infections due to P. falciparum become clinically apparent within one month after exposure [3-5]. Longer incubation periods are more likely in semi-immune individuals and individuals taking ineffective malaria prophylaxis.

The incubation period for relapsing species Plasmodium vivax and Plasmodium ovale is also about two weeks but illness can occur months after the initial infection due to activation of residual hypnozoites in the liver [3,6,7]. Relapses generally occur within two to three years of infection; there is one report of P. vivax infection presenting in a patient four years following departure from an endemic area [8].

The incubation period for Plasmodium malariae is about 18 days; however, low-grade asymptomatic infections can very rarely persist for years (table 1). P. falciparum and P. malariae have no dormant (hypnozoite) phase, hence do not relapse. (See "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae".)

Two nonhuman primate malarias, Plasmodium knowlesi and Plasmodium simium, have been shown to infect humans in Southeast Asia and Brazil, respectively; P. knowlesi resembles P. malariae, and P. simium resembles P. vivax (microscopically and by polymerase chain reaction) [9].

CLINICAL MANIFESTATIONS

Uncomplicated malaria — Uncomplicated falciparum malaria consists of symptomatic infection due to P. falciparum (established via a positive parasitologic test) in a patient who can swallow medicines, in the absence of symptoms and signs consistent with severe malaria (table 2).

Malaria should be suspected in patients with any febrile illness if they have had exposure to a region where malaria is endemic [1,2,7]. The initial symptoms of malaria are nonspecific and may also include tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis (sweating), headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias [2,7]. Patients are considered to have uncomplicated malaria in the setting of mild symptoms of malaria and a positive parasitological test in the absence of signs of severe malaria [10]; patients with uncomplicated disease are generally able to swallow antimalarial drugs.

Physical findings may include manifestations of anemia and a palpable spleen. Anemia is common among young children in endemic areas and is often due to multiple causes in addition to malaria (including iron and other nutritional deficiencies as well as intestinal geohelminth infection) [11]. Mild jaundice may also develop in patients with otherwise uncomplicated falciparum malaria. Splenic enlargement is a frequent finding among otherwise healthy individuals in endemic areas; this condition may reflect repeated malaria infections or infection due to other causes. The spleen often shrinks due to infarctions after multiple malaria exposures, such that it is not palpable. In nonimmune individuals with acute malaria, the spleen may become palpable after several days. In such patients, lack of anemia early in clinical course is common and should not rule out the possibility of malaria.

Laboratory evaluation may demonstrate parasitemia (usually <5000 parasites/microL of blood, <0.1 percent parasitized red blood cells [RBCs]), anemia, thrombocytopenia, elevated transaminases, mild coagulopathy, and elevated blood urea nitrogen (BUN) and creatinine.

Uncomplicated malaria can occur with any Plasmodium species. Although falciparum malaria is the most virulent, it is often not possible to determine the species of malaria infection on clinical grounds alone; there are some unique characteristics associated with each species, and P. vivax, P. ovale, P. malariae, and P. knowlesi are discussed in detail separately. (See "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae" and "Non-falciparum malaria: Plasmodium knowlesi".)

Early in the course of malaria infection, febrile paroxysms occur at irregular intervals each day. The temperature of nonimmune individuals and children may rise above 40ºC and may occur in conjunction with tachycardia and/or delirium. Febrile convulsions may occur among children in the setting of malaria due to any species. However, generalized seizures are associated with falciparum and may herald the development of cerebral malaria. (See 'Cerebral malaria' below.)

Later in the course of infection, rupture of infected red cells can become synchronous following concurrent schizont rupture and release of merozoites from erythrocytes (figure 1). Febrile paroxysms may occur every other day for P. vivax, P. ovale, and P. falciparum and every third day for P. malariae. Paroxysms occurring at regular intervals are more common in the setting of infection due to P. vivax or P. ovale than P. falciparum. With improvements in early diagnosis and treatment, this traditional description of cyclic fever is seen infrequently.

Febrile illness may reflect concomitant infection. The lower the parasitemia, the greater the chance of a lower respiratory tract, intestinal, or bloodstream bacterial or viral infection [12]. (See 'Concomitant infection' below.)

Severe malaria — Severe malaria is defined as presence of P. falciparum parasitemia and one or more of the manifestations in the table (table 2). P. knowlesi, which is restricted to Southeast Asia, can also cause severe disease. It is acquired in forested regions as a predominately zoonotic infection via mosquito transmission from simian hosts (Macaca fascicularis and Macaca nemestrina). (See "Non-falciparum malaria: Plasmodium knowlesi".)

General principles — Manifestations of severe malaria are summarized in the table (table 2) [10,13].

Many of the clinical findings are the result of the parasitized (and nonparasitized) RBCs adhering to small blood vessels ("cytoadherence") causing small infarcts, capillary leakage, and organ dysfunction; these include the following [7,14,15]:

Altered consciousness with or without seizures

Respiratory distress or acute respiratory distress syndrome (ARDS)

Circulatory collapse

Metabolic acidosis

Renal failure, hemoglobinuria ("blackwater fever")

Hepatic failure

Coagulopathy with or without disseminated intravascular coagulation

Severe anemia or massive intravascular hemolysis

Hypoglycemia

Physical findings may include pallor, petechiae, jaundice, hepatomegaly, and/or splenomegaly. Splenic rupture has been described. Diagnostic evaluation may demonstrate the following: parasitemia ≥4 to 10 percent, anemia, thrombocytopenia, coagulopathy, elevated transaminases, elevated BUN/creatinine, acidosis, and hypoglycemia [7,16,17]. Thrombocytopenia has been associated with increased risk of death from falciparum or vivax malaria, particularly in the setting of concurrent severe anemia [18].

The clinical manifestations of severe malaria vary with age and geography. In areas where malaria is endemic, young children (ages two to five years) are at high risk for severe malaria, as are pregnant women. Older children and adults develop partial immunity to febrile malaria episodes (but not to malaria infection) after repeated infection and thus are at lower risk for severe disease [19]. Travelers to areas where malaria is endemic with no previous exposure to malaria parasites are at higher risk for progression to severe disease if infected with P. falciparum [20]. (See 'Children versus adults' below.)

While most severe malaria is usually due to P. falciparum, patients with severe malaria due to P. vivax have also been described. Patients with severe P. vivax may manifest pulmonary complications and ARDS [21]. Those at greatest risk for severe disease include nonimmune individuals, immunocompromised patients (including asplenic individuals), children 6 to 59 months of age, and pregnant women [7,22]. Increasing parasitemia is associated with increasing disease severity. Semi-immune individuals may have substantial parasitemia with few or no clinical manifestations. However, some severely ill or inadequately treated patients may have a low but rising parasitemia when first seen by a clinician. (See "Laboratory tools for diagnosis of malaria".)

Manifestations of complicated malaria can portend a grave prognosis; such patients should receive a prompt and thorough evaluation and immediate treatment [23,24]. (See "Treatment of severe malaria".)

Cerebral malaria — Cerebral malaria is an encephalopathy that presents with impaired consciousness, delirium, and/or seizures; focal neurologic signs are unusual. The onset may be gradual or sudden following a convulsion. The severity depends on a combination of factors including parasite virulence, host immune response, and time between onset of symptoms and initiation of therapy.

Risk factors for cerebral malaria include age (children and older adults), pregnancy, poor nutritional status, HIV infection, host genetic susceptibility, and history of splenectomy [25-28]. Among adults, cerebral malaria occurs more commonly in nonimmune individuals than in those living in highly endemic areas (where cerebral malaria is more common in children). In a study of 19,560 Kenyan children with malaria, neurologic involvement was observed in 48 percent of cases; presentation included seizures, prostration, impaired consciousness, and agitation (in 38, 21, 13, and 3 percent of cases, respectively) [27].

The mean opening pressure in patients with cerebral malaria is about 16 cm of cerebrospinal fluid (CSF). Laboratory examination may be normal or may demonstrate slightly elevated total protein level and cell count. In a study comparing CSF findings from 12 children with cerebral malaria and 14 children with presumed viral encephalitis, patients with cerebral malaria had lower white cell count, glucose, and protein levels [29]. Children with malaria had mean white cell count of 0 cells/microL (range 0 to 4 cells/microL); children with viral encephalitis had mean white cell count of 4 cells/microL (range 0 to 9 cells/microL). A CSF glucose concentration below 3.4 mmol/L (61 mg/dL) was the best discriminator of cerebral malaria from presumed viral encephalitis.

Retinal hemorrhages may be observed in 30 to 40 percent of cases via pupillary dilation and indirect ophthalmoscopy; without pupillary dilation, this finding may be seen in approximately 15 percent of cases. Other funduscopic abnormalities include discrete spots of retinal opacification (30 to 60 percent), papilledema (8 percent among children, rare among adults), cotton wool spots (<5 percent), and decolorization of a retinal vessel or segment of vessel (picture 1 and picture 2 and picture 3) [30].

Cerebral edema and elevated intracranial pressure may contribute to a fatal outcome (picture 4). In one study including 164 children with cerebral malaria, approximately 84 percent of deaths occurred among individuals with evidence of severe brain swelling on magnetic resonance imaging at admission (picture 4); such swelling was noted among 27 percent of survivors [31].

Signs of cerebral malaria should be evaluated and managed promptly as cerebral malaria can progress rapidly to coma and death. If untreated, cerebral malaria is almost universally fatal; with treatment, mortality is 15 to 20 percent [32].

Among survivors of cerebral malaria, neurologic sequelae are more common among children than adults (about 15 versus 3 percent, respectively). Residual deficits may include hemiplegia, cerebral palsy, cortical blindness, deafness, epilepsy, language deficit, and impaired cognition [32,33]. Such sequelae are more likely among patients with other grave prognostic indicators including hypoglycemia, acidosis, severe anemia, repeated seizures, and deep coma. Postmalaria neurologic syndrome is an autoimmune encephalitis that manifests within two months of treatment and resolution of cerebral malaria. The condition is rare, presents often with seizures, and responds to parenteral steroids [34].

Hypoglycemia — Hypoglycemia is a common complication of severe malaria, although the usual signs (sweating, tachycardia, neurologic impairment) are difficult to distinguish from systemic symptoms due to severe malaria. Hypoglycemia occurs as a result of the following factors:

Diminished hepatic gluconeogenesis

Depletion of liver glycogen stores

Increase in the consumption of glucose by the host (and, to a much lesser extent, the parasite)

Quinine-induced hyperinsulinemia

Hypoglycemia is associated with a poor prognosis, particularly in children and pregnant women.

Acidosis — Acidosis is an important cause of death from severe malaria; it is caused by several factors, including:

Anaerobic glycolysis in host tissues where sequestered parasites interfere with microcirculatory flow

Parasite lactate production

Hypovolemia

Insufficient hepatic and renal lactate clearance

The prognosis of severe acidosis is poor.

Renal impairment — Renal impairment is common among adults with severe falciparum malaria; it is less frequently described among children [35]. The pathogenesis of renal failure is uncertain but may be related to erythrocyte sequestration interfering with renal microcirculatory flow and metabolism. Other potential factors include hypovolemia and hemolysis [36]. Large amounts of hemoglobin and malarial pigments may be present in the urine secondary to intravascular hemolysis. This uncommonly manifests in very dark urine following several attacks of falciparum malaria; mortality is high. Renal impairment can manifest as acute tubular necrosis (both clinically and pathologically), although renal cortical necrosis does not occur.

Noncardiogenic pulmonary edema — Noncardiogenic pulmonary edema (eg, adult respiratory distress syndrome) may be observed in adults with severe falciparum malaria [37]. The pathogenesis is uncertain but may be related to sequestration of parasitized red cells in the lungs and/or cytokine-induced leakage from the pulmonary vasculature. This complication may develop even after several days of antimalarial therapy and can be aggravated by overly vigorous administration of intravenous fluid [23]. Noncardiogenic pulmonary edema can also develop in otherwise uncomplicated vivax malaria. (See "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults".)

Children with severe anemia may present with deep, labored respirations. This is usually due to metabolic acidosis (often compounded by hypovolemia), although previously it has been attributed to "anemic congestive cardiac failure."

Hematologic abnormalities — Anemia is usually mild to moderate, though severe anemia may occur in the setting of P. falciparum malaria. In one series including 100 Canadian travelers, patients with malaria presented with anemia in 41 percent of cases [38]. White blood cell counts were elevated above 9.8 x 109/L in 3 percent of patients but were less than 5.0 x 109/L in 48 percent. Platelets were low in 83 percent of P. vivax-infected patients (mean 102 x 109/L) and in 62 percent of P. falciparum-infected patients (mean 137 x 109/L).

Children in endemic areas with serial episodes of malaria infection may develop severe chronic anemia. In nonimmune individuals and in areas with unstable transmission, anemia can develop acutely. Anemia in the setting of malaria occurs as a result of the following factors:

Hemolysis of parasitized red cells

Increased splenic sequestration and clearance of erythrocytes with diminished deformability

Cytokine suppression of hematopoiesis

Shortened erythrocyte survival

Repeated infections and ineffective treatments

Additional information regarding these mechanisms is presented separately. (See "Anemia in malaria".)

Coagulopathy is common in the setting of falciparum malaria; bleeding with evidence of disseminated intravascular coagulation occurs in <5 percent of patients with severe malaria. (See "Evaluation and management of disseminated intravascular coagulation (DIC) in adults".)

Liver dysfunction — Mild jaundice due to hemolysis in malaria is common. Severe jaundice due to hemolysis, hepatocyte injury, and cholestasis may occur in the setting of P. falciparum infection; this manifestation is more common among adults than children. Liver dysfunction together with renal impairment and other organ dysfunction portend a poor prognosis [7].

Concomitant infection — There appears to be a biological association between malaria, HIV, malnutrition, and invasive bacterial infections. These conditions occur often in malarious areas, as do geohelminths; the latter contribute greatly to anemia and malnutrition, especially in children [11,39].

Bacterial infection — Septicemia may complicate severe malaria, particularly in children [39]. In endemic areas, Salmonella bacteremia has been associated with P. falciparum infections [40]. Chest infections and catheter-induced urinary tract infections are common among patients who are unconscious for ≥3 days. Aspiration pneumonia may follow generalized seizures.

HIV infection — HIV and malaria often coexist. Both conditions induce cell-medicated immunodepression.

HIV infection is associated with increased susceptibility to malaria, higher parasitemia, and increased risk for recurrent malaria infection, particularly in patients with CD4 counts <200 cells/microL [41]. In addition, malaria infection in HIV-infected patients has been associated with CD4 cell decline relative to HIV-infected patients without malaria [42].

Malaria infection has been associated with a transient increase in HIV viral load in some circumstances; however, this does not appear to hasten progression to AIDS [43-47]. In one study of pregnant women in Tanzania, HIV-infected women with low baseline parasitemia had higher viral loads than HIV-infected women with no detectable parasitemia [44].

If HIV viral loads are used to monitor the response to antiretroviral therapy, testing should be delayed for approximately two months among patients with recent malaria infection.

Children versus adults — Clinical manifestations of malaria vary between children and adults [48]. Seizures and severe anemia are more common in children, whereas hyperparasitemia, acute renal failure, and jaundice are more common in adults [48]. Cerebral malaria (with coma), shock, acidosis, and respiratory arrest may occur at any age [48].

It can be difficult to distinguish congenital malaria infection from malaria infection acquired as a newborn. Among infants with congenital malaria, onset of clinical manifestations usually occurs at two to eight weeks of age; signs and symptoms include poor feeding, fever, vomiting, diarrhea, and irritability. Anemia, thrombocytopenia, and hyperbilirubinemia are common [49]. Splenomegaly is more common than hepatomegaly. Issues related to vertical transmission of malaria are discussed separately. (See "Malaria in pregnancy: Epidemiology, clinical manifestations, diagnosis, and outcome", section on 'Vertical transmission'.)

Recurrent malaria infection — Recurrence of malaria can occur as a result of treatment failure (recrudescence) or reinfection; these may be difficult to distinguish. Both recrudescent and relapsing infections manifest as return of disease after its apparent cessation. Recrudescence occurs most often within days or weeks; relapse occurs within weeks or months. In recrudescence, parasites remain in the bloodstream undetected due to ineffective treatment or host immunological response (or both). In relapse, new hypnozoites are released from liver cells causing another parasitemia. P. falciparum is the usual cause of recrudescent infections, although P. malariae can remain dormant for years; P. vivax and P. ovale may cause relapse months after the primary blood stage infection is cured, as these species have hypnozoite forms.

DIAGNOSIS — Uncomplicated falciparum malaria consists of symptomatic P. falciparum infection with a positive parasitologic test, in the absence of symptoms consistent with severe malaria (table 2). Severe malaria is defined as presence of P. falciparum parasitemia and one or more of the manifestations in the table (table 2). (See 'Severe malaria' above.)

Malaria should be suspected in the setting of fever (temperature ≥37.5°C) and relevant epidemiologic exposure (residence in or travel to an area where malaria is endemic; most infections due to P. falciparum become clinically apparent within one month after exposure) [10]. In addition, for endemic areas with stable transmission and for areas with seasonal malaria during high-transmission season, malaria should be suspected in children with palmar pallor or hemoglobin concentration <8 g/dL.

The diagnosis of malaria is definitively established in the setting of symptoms consistent with malaria and a positive malaria diagnostic test; diagnostic tools include light microscopy of blood smears and rapid diagnostic tests. For patients with suspected malaria, definitive diagnosis should be established [10]. If initial diagnostic evaluation is negative and clinical suspicion for malaria persists, follow-up testing should be performed each day for two more days [50]. (See "Laboratory tools for diagnosis of malaria", section on 'General principles'.)

If diagnostic tools are not readily available and there is clinical suspicion for P. falciparum infection, it may be reasonable to make a presumptive diagnosis (and treat empirically), given the potential severity of infection. Making a presumptive diagnosis depends on individual patient circumstances including epidemiologic exposure, clinical manifestations such as fever, and suggestive laboratory findings including anemia, in the absence of a clear alternative diagnosis. However, the clinical presentation of malaria overlaps with many other causes, and even in endemic areas, clinical diagnosis of malaria is frequently incorrect [51-56]. Furthermore, empiric therapy may negatively affect the accuracy of subsequent diagnostic testing.

In sub-Saharan Africa (where the burden of malaria is greatest), a definitive diagnosis of malaria among patients with fever is established in less than half of cases [57-59]. One systemic review and meta-analysis including 21 studies (14 studies of endemic malaria and 7 studies of imported malaria) assessed the predictive value of clinical findings for diagnosis of malaria [60]. In endemic areas, presence of splenomegaly and hepatomegaly were associated with increased likelihood of malaria (likelihood ratios [LRs] 3.3 [95% CI 2.0-4.7] and 2.4 [95% CI 1.6-3.6, respectively]). In returning travelers, presence of splenomegaly (LR 6.5, 95% CI 3.9-11.0), jaundice or icterus (LR 4.5, 95% CI 1.7-12.0), or pallor (LR 2.8, 95% CI 1.7-4.6) were associated with increased the likelihood of malaria. In addition, malaria was more likely in the setting of thrombocytopenia and hyperbilirubinemia (odds ratios 74.0 [95% CI 9.2-601.0] and 11 [95% CI 8-15], respectively).

Individuals with acquired partial immunity due to repeated exposures in endemic settings may have asymptomatic parasitemia. There is no diagnostic test capable of distinguishing between parasitemia causing clinical malaria and febrile illness due to another cause in a patient who also has asymptomatic parasitemia. (See 'Differential diagnosis' below.)

Diagnostic tools include light microscopy and rapid diagnostic tests. Detailed discussion regarding these tools is presented separately. (See "Laboratory tools for diagnosis of malaria".)

DIFFERENTIAL DIAGNOSIS — The differential diagnosis of malaria includes:

Dengue fever – Dengue fever can cause malaise, headache, fatigue, abdominal discomfort, and muscle aches in association with fever. Myalgia due to dengue fever is usually more severe than myalgia due to malaria. The diagnosis is established with serology. (See "Dengue virus infection: Clinical manifestations and diagnosis".)

Chikungunya – Chikungunya resembles dengue but is milder and self-limiting, often with a rash. The diagnosis is established via serology. (See "Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'.)

Meningitis – The headache of malaria may be severe, although there is no neck stiffness or photophobia as seen with bacterial or viral meningitis. Malaria is not associated with a rash (unlike meningococcal septicemia). The diagnosis of bacterial meningitis is established via lumbar puncture and culture. (See "Clinical features and diagnosis of acute bacterial meningitis in adults".)

Pneumonia – Clinical manifestations of pneumonia include fever, cough, dyspnea, and sputum production. Patients with pneumonia may have intercostal retractions and other signs of labored breathing. The diagnosis is of pneumonia established via chest radiography and sputum culture. (See "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults".)

Sepsis due to bacteremia – Sepsis due to bacteremia may present with fever, tachycardia, and altered mental status; diagnosis requires blood culture.

Typhoid fever – Clinical manifestations of typhoid fever include fever, bradycardia, abdominal pain, and rash. The diagnosis is established by stool and/or blood culture. (See "Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever".)

Leptospirosis – Leptospirosis is associated with fever, rigors, myalgia, and headache. Myalgia due to leptospirosis is usually more severe than in malaria; leptospirosis may also be associated with petechial hemorrhages in the skin or mucous membranes. The diagnosis is established by serologic testing. (See "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis".)

Viral hemorrhagic fever – Viral hemorrhagic fever is associated with fever, malaise, and systemic symptoms. It may be associated with petechial hemorrhages in the skin or mucous membranes; this occurs in severe malaria only rarely. The diagnosis is established by immunoassay or nucleic acid testing. (See "Clinical manifestations and diagnosis of Ebola virus disease".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Malaria".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient education: Malaria (The Basics)")

SUMMARY

In areas where malaria is endemic, groups at high risk for severe malaria and its consequences include young children (6 to 59 months) and pregnant women. Older children and adults develop partial immunity after repeated infection and are at relatively low risk for severe disease. As disease incidence wanes, older age groups will become more susceptible due to decreasing immunity. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and are at very high risk for severe disease if infected with Plasmodium falciparum. (See 'Introduction' above.)

The incubation period for P. falciparum infection is usually 12 to 14 days (range 7 to 30 days). Longer incubation periods are more likely in semi-immune individuals and individuals taking inadequate malaria prophylaxis at the time of infection. The relapsing malarias (Plasmodium vivax and Plasmodium ovale) can cause clinical illness several weeks or months after the initial infection due to presence of hypnozoites in the liver. (See 'Incubation period' above.)

Malaria should be suspected in the setting of fever (temperature ≥37.5°C) and relevant epidemiologic exposure (residence in or travel to an area where malaria is endemic. The diagnosis of malaria is definitively established in the setting of symptoms consistent with malaria and a positive malaria diagnostic test; diagnostic tools include light microscopy and rapid diagnostic tests. For patients with suspected malaria, definitive diagnosis should be established whenever possible. (See 'Clinical manifestations' above.)

Uncomplicated falciparum malaria consists of symptomatic infection due to P. falciparum (established via a positive parasitologic test) in a patient who can swallow medicines, in the absence of symptoms and signs consistent with severe malaria (table 2). Severe malaria is defined as presence of P. falciparum parasitemia and one or more of the manifestations in the table (table 2). General principles regarding diagnosis of malaria are discussed above. (See 'Diagnosis' above.)

If diagnostic tools are not readily available and there is clinical suspicion for P. falciparum infection, it may be reasonable to make a presumptive diagnosis (and treat empirically), given the potential severity of infection. Making a presumptive diagnosis depends on individual patient circumstances including epidemiologic exposure, clinical manifestations such as fever, and suggestive laboratory findings including anemia, in the absence of a clear alternative diagnosis. However, the clinical presentation of malaria overlaps with many other causes. (See 'Diagnosis' above.)

Common manifestations among children with severe malaria include convulsions, coma, hypoglycemia, metabolic acidosis, severe anemia, and neurodevelopmental sequelae. Findings observed more frequently among adults than children include severe jaundice, acute renal failure, and acute pulmonary edema. (See 'Children versus adults' above.)

The differential diagnosis of malaria includes viral infection, meningitis, pneumonia, bacteremia, leptospirosis, typhus, and enteric fever. Malaria can coexist with these entities and with HIV, malnutrition, and intestinal geohelminths. (See 'Differential diagnosis' above.)

REFERENCES

  1. Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.
  2. Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.
  3. Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.
  4. World Health Organization. International travel and health: Malaria. http://www.who.int/ith/diseases/malaria/en/ (Accessed on July 28, 2015).
  5. Centers for Disease Control and Prevention. Malaria: Disease. http://www.cdc.gov/malaria/about/disease.html (Accessed on July 28, 2015).
  6. Mühlberger N, Jelinek T, Gascon J, et al. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 2004; 3:5.
  7. Ashley EA, White NJ. Harrison’s Principles of Internal Medicine, 20th ed, Jameson JL, Fauci AS, Kasper DL et al (Eds), McGraw Hill, New York 2018.
  8. Durante Mangoni E, Severini C, Menegon M, et al. Case report: An unusual late relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2003; 68:159.
  9. Grigg MJ, Snounou G. Plasmodium simium: a Brazilian focus of anthropozoonotic vivax malaria? Lancet Glob Health 2017; 5:e961.
  10. World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on January 04, 2021).
  11. Brooker S, Akhwale W, Pullan R, et al. Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg 2007; 77:88.
  12. Hogan B, Eibach D, Krumkamp R, et al. Malaria Coinfections in Febrile Pediatric Inpatients: A Hospital-Based Study From Ghana. Clin Infect Dis 2018; 66:1838.
  13. Centers for Disease Control and Prevention. Treatment Guidelines: Treatment of Malaria (Guidelines for Clinicians), 2013. http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf (Accessed on May 11, 2020).
  14. Severe malaria. Trop Med Int Health 2014; 19 Suppl 1:7.
  15. White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.
  16. Devarbhavi H, Alvares JF, Kumar KS. Severe falciparum malaria simulating fulminant hepatic failure. Mayo Clin Proc 2005; 80:355.
  17. Field JW. Blood examination and prognosis in acute falciparum malaria. Trans R Soc Trop Med Hyg 1949; 43:33.
  18. Lampah DA, Yeo TW, Malloy M, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis 2015; 211:623.
  19. Bejon P, Warimwe G, Mackintosh CL, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917.
  20. Phillips A, Bassett P, Zeki S, et al. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis 2009; 48:871.
  21. McGready R, Wongsaen K, Chu CS, et al. Uncomplicated Plasmodium vivax malaria in pregnancy associated with mortality from acute respiratory distress syndrome. Malar J 2014; 13:191.
  22. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64:28.
  23. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94 Suppl 1:S1.
  24. Stanley J. Malaria. Emerg Med Clin North Am 1997; 15:113.
  25. Reyburn H, Mbatia R, Drakeley C, et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 2005; 293:1461.
  26. Ranque S, Safeukui I, Poudiougou B, et al. Familial aggregation of cerebral malaria and severe malarial anemia. J Infect Dis 2005; 191:799.
  27. Idro R, Ndiritu M, Ogutu B, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007; 297:2232.
  28. Hochman SE, Madaline TF, Wassmer SC, et al. Fatal Pediatric Cerebral Malaria Is Associated with Intravascular Monocytes and Platelets That Are Increased with HIV Coinfection. MBio 2015; 6:e01390.
  29. Jakka SR, Veena S, Atmakuri RM, Eisenhut M. Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. Cerebrospinal Fluid Res 2006; 3:8.
  30. Lewallen S, Bronzan RN, Beare NA, et al. Using malarial retinopathy to improve the classification of children with cerebral malaria. Trans R Soc Trop Med Hyg 2008; 102:1089.
  31. Seydel KB, Kampondeni SD, Valim C, et al. Brain swelling and death in children with cerebral malaria. N Engl J Med 2015; 372:1126.
  32. Mung'Ala-Odera V, Snow RW, Newton CR. The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg 2004; 71:64.
  33. Christensen SS, Eslick GD. Cerebral malaria as a risk factor for the development of epilepsy and other long-term neurological conditions: a meta-analysis. Trans R Soc Trop Med Hyg 2015; 109:233.
  34. Sahuguet J, Poulet A, Bou Ali H, et al. Postmalaria Neurologic Syndrome-Autoimmune Encephalitis With Anti-Voltage-Gated Potassium-Channel Antibodies. Ann Intern Med 2017; 167:70.
  35. Conroy AL, Hawkes M, Elphinstone RE, et al. Acute Kidney Injury Is Common in Pediatric Severe Malaria and Is Associated With Increased Mortality. Open Forum Infect Dis 2016; 3:ofw046.
  36. Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol 2000; 11:2147.
  37. Taylor WR, Hanson J, Turner GD, et al. Respiratory manifestations of malaria. Chest 2012; 142:492.
  38. Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis 1998; 27:142.
  39. Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009; 49:336.
  40. Morpeth SC, Ramadhani HO, Crump JA. Invasive non-Typhi Salmonella disease in Africa. Clin Infect Dis 2009; 49:606.
  41. Hendriksen IC, Ferro J, Montoya P, et al. Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique. Clin Infect Dis 2012; 55:1144.
  42. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr 2006; 41:129.
  43. Alemu A, Shiferaw Y, Addis Z, et al. Effect of malaria on HIV/AIDS transmission and progression. Parasit Vectors 2013; 6:18.
  44. Franke MF, Spiegelman D, Ezeamama A, et al. Malaria parasitemia and CD4 T cell count, viral load, and adverse HIV outcomes among HIV-infected pregnant women in Tanzania. Am J Trop Med Hyg 2010; 82:556.
  45. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233.
  46. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999; 13:487.
  47. Subramaniam K, Plank RM, Lin N, et al. Plasmodium falciparum Infection Does Not Affect Human Immunodeficiency Virus Viral Load in Coinfected Rwandan Adults. Open Forum Infect Dis 2014; 1:ofu066.
  48. Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151.
  49. Hulbert TV. Congenital malaria in the United States: report of a case and review. Clin Infect Dis 1992; 14:922.
  50. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.
  51. Ndyomugyenyi R, Magnussen P, Clarke S. Diagnosis and treatment of malaria in peripheral health facilities in Uganda: findings from an area of low transmission in south-western Uganda. Malar J 2007; 6:39.
  52. Ndyomugyenyi R, Magnussen P, Clarke S. Malaria treatment-seeking behaviour and drug prescription practices in an area of low transmission in Uganda: implications for prevention and control. Trans R Soc Trop Med Hyg 2007; 101:209.
  53. Luxemburger C, Nosten F, Kyle DE, et al. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg 1998; 92:45.
  54. Chandramohan D, Carneiro I, Kavishwar A, et al. A clinical algorithm for the diagnosis of malaria: results of an evaluation in an area of low endemicity. Trop Med Int Health 2001; 6:505.
  55. Mwangi TW, Mohammed M, Dayo H, et al. Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health 2005; 10:530.
  56. Vinnemeier CD, Schwarz NG, Sarpong N, et al. Predictive value of fever and palmar pallor for P. falciparum parasitaemia in children from an endemic area. PLoS One 2012; 7:e36678.
  57. Patrick Kachur S, Schulden J, Goodman CA, et al. Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004. Trop Med Int Health 2006; 11:441.
  58. Hopkins H, Bebell L, Kambale W, et al. Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis 2008; 197:510.
  59. Olivar M, Develoux M, Chegou Abari A, Loutan L. Presumptive diagnosis of malaria results in a significant risk of mistreatment of children in urban Sahel. Trans R Soc Trop Med Hyg 1991; 85:729.
  60. Taylor SM, Molyneux ME, Simel DL, et al. Does this patient have malaria? JAMA 2010; 304:2048.
Topic 5709 Version 36.0

References

1 : Fever in returned travelers: results from the GeoSentinel Surveillance Network.

2 : Imported malaria. Clinical presentation and examination of symptomatic travelers.

3 : Delayed onset of malaria--implications for chemoprophylaxis in travelers.

4 : Delayed onset of malaria--implications for chemoprophylaxis in travelers.

5 : Delayed onset of malaria--implications for chemoprophylaxis in travelers.

6 : Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop.

7 : Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop.

8 : Case report: An unusual late relapse of Plasmodium vivax malaria.

9 : Plasmodium simium: a Brazilian focus of anthropozoonotic vivax malaria?

10 : Plasmodium simium: a Brazilian focus of anthropozoonotic vivax malaria?

11 : Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control.

12 : Malaria Coinfections in Febrile Pediatric Inpatients: A Hospital-Based Study From Ghana.

13 : Malaria Coinfections in Febrile Pediatric Inpatients: A Hospital-Based Study From Ghana.

14 : Severe malaria.

15 : The treatment of malaria.

16 : Severe falciparum malaria simulating fulminant hepatic failure.

17 : Blood examination and prognosis in acute falciparum malaria.

18 : Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia.

19 : Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure.

20 : Risk factors for severe disease in adults with falciparum malaria.

21 : Uncomplicated Plasmodium vivax malaria in pregnancy associated with mortality from acute respiratory distress syndrome.

22 : The burden of malaria in pregnancy in malaria-endemic areas.

23 : Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.

24 : Malaria.

25 : Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria.

26 : Familial aggregation of cerebral malaria and severe malarial anemia.

27 : Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children.

28 : Fatal Pediatric Cerebral Malaria Is Associated with Intravascular Monocytes and Platelets That Are Increased with HIV Coinfection.

29 : Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis.

30 : Using malarial retinopathy to improve the classification of children with cerebral malaria.

31 : Brain swelling and death in children with cerebral malaria.

32 : The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa.

33 : Cerebral malaria as a risk factor for the development of epilepsy and other long-term neurological conditions: a meta-analysis.

34 : Postmalaria Neurologic Syndrome-Autoimmune Encephalitis With Anti-Voltage-Gated Potassium-Channel Antibodies.

35 : Acute Kidney Injury Is Common in Pediatric Severe Malaria and Is Associated With Increased Mortality.

36 : Malarial acute renal failure.

37 : Respiratory manifestations of malaria.

38 : Imported malaria: prospective analysis of problems in diagnosis and management.

39 : HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria.

40 : Invasive non-Typhi Salmonella disease in Africa.

41 : Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique.

42 : Association between malaria and CD4 cell count decline among persons with HIV.

43 : Effect of malaria on HIV/AIDS transmission and progression.

44 : Malaria parasitemia and CD4 T cell count, viral load, and adverse HIV outcomes among HIV-infected pregnant women in Tanzania.

45 : Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.

46 : The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration.

47 : Plasmodium falciparum Infection Does Not Affect Human Immunodeficiency Virus Viral Load in Coinfected Rwandan Adults.

48 : The relationship between age and the manifestations of and mortality associated with severe malaria.

49 : Congenital malaria in the United States: report of a case and review.

50 : Treatment of malaria in the United States: a systematic review.

51 : Diagnosis and treatment of malaria in peripheral health facilities in Uganda: findings from an area of low transmission in south-western Uganda.

52 : Malaria treatment-seeking behaviour and drug prescription practices in an area of low transmission in Uganda: implications for prevention and control.

53 : Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission.

54 : A clinical algorithm for the diagnosis of malaria: results of an evaluation in an area of low endemicity.

55 : Clinical algorithms for malaria diagnosis lack utility among people of different age groups.

56 : Predictive value of fever and palmar pallor for P. falciparum parasitaemia in children from an endemic area.

57 : Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.

58 : Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda.

59 : Presumptive diagnosis of malaria results in a significant risk of mistreatment of children in urban Sahel.

60 : Does this patient have malaria?